Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong SAR.
Shivanand Desai Center for Digestive Disorders, Deenanath Mangeshkar Hospital and Research Center, Pune, India.
Dig Endosc. 2020 Mar;32(3):391-398. doi: 10.1111/den.13494. Epub 2019 Aug 30.
A novel self-approximating lumen-apposing metallic stent (LAMS; Niti-S Spaxus, Taewoong Medical, Gyeonggi-do, Korea) has recently become available. The aim of the present study was to evaluate the outcomes for drainage of pancreatic fluid collections (PFC).
This was a prospective international multicentered study conducted in six high-volume institutions across Asia. Consecutive patients suffering from pancreatic pseudocyst or walled-off pancreatic necrosis (WOPN) requiring endoscopic ultrasonography-guided drainage were recruited. Outcomes included technical and clinical success, adverse events, procedural events, interventions through the stent and recurrence rates.
Between August 2016 and November 2017, 59 patients were recruited to this study. Thirty-nine patients (66.1%) had WOPN and mean (SD) size of PFC was 11.5 (5.1) cm. Technical and clinical success rates were 100%. Mean (SD) procedural time was 35.0 (17.2) minutes. Sixteen-millimeter stents were used in 66.1% of the patients. Fifty-four sessions of necrosectomy were carried out with the stent in situ in 17 patients. Stent-related adverse event (AE) rate was 6.8%. Three patients (5.1%) suffered from bleeding after stenting and one required angiographic embolization. Two patients (3.4%) suffered from recurrence during a mean (SD) follow-up time of 325.6 (355.5) days. There were no differences in outcomes between those with pseudocysts or WOPN except for the duration of hospital stay (P = 0.012).
Use of a self-approximating LAMS for drainage of PFC was safe and effective. Endoscopic necrosectomy could be carried out through the stent with ease. The device was associated with a low rate of stent-related AE.
一种新型的自膨式吻合金属支架(LAMS;Niti-S Spaxus,Taewoong Medical,京畿道,韩国)已被应用于临床。本研究旨在评估其用于引流胰腺液体积聚(PFC)的效果。
这是一项在亚洲六个高容量中心进行的前瞻性国际多中心研究。连续招募因胰腺假性囊肿或包裹性坏死(WOPN)而需要超声内镜引导引流的患者。结果包括技术和临床成功率、不良事件、操作事件、支架内干预和复发率。
2016 年 8 月至 2017 年 11 月,共招募了 59 例患者。其中 39 例(66.1%)为 WOPN,PFC 的平均(SD)大小为 11.5(5.1)cm。技术和临床成功率均为 100%。平均(SD)操作时间为 35.0(17.2)分钟。16mm 支架用于 66.1%的患者。17 例患者中有 54 次通过支架进行了坏死组织切除术。支架相关不良事件(AE)发生率为 6.8%。3 例(5.1%)患者在支架置入后发生出血,1 例需要血管造影栓塞。2 例(3.4%)患者在平均(SD)随访 325.6(355.5)天后复发。假性囊肿和 WOPN 患者的结果无差异,除住院时间(P=0.012)外。
使用自膨式 LAMS 引流 PFC 是安全有效的。通过支架可以轻松进行内镜下坏死组织切除术。该装置与支架相关的 AE 发生率低。